Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
2.780
-0.080 (-2.80%)
Nov 13, 2026, 4:00 PM EST - Market closed
Upstream Bio Employees
Upstream Bio had 75 employees as of December 31, 2025. The number of employees increased by 23 or 44.23% compared to the previous year. That makes Upstream Bio the 33,204th largest employer in the world and 4,334th in the United States.
Employees
75
Change (1Y)
23
Growth (1Y)
44.23%
Revenue / Employee
$38,267
Profits / Employee
-$2,185,920
Market Cap
152.38M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 75 | 23 | 44.23% |
| Dec 31, 2024 | 52 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 184 |
| Fate Therapeutics | 161 |
| Sutro Biopharma | 129 |
| enGene Therapeutics | 82 |
| Armata Pharmaceuticals | 61 |
| Sionna Therapeutics | 59 |
| ALX Oncology Holdings | 48 |
| Protara Therapeutics | 46 |
UPB News
- 4 days ago - Upstream Bio price target lowered to $18 from $36 at H.C. Wainwright - TheFly
- 5 days ago - Upstream Bio reports Q3 revenue $395,000, consensus $480,290 - TheFly
- 5 days ago - Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress - GlobeNewsWire
- 5 days ago - Upstream Bio Earnings release: Q3 2026 - Filings
- 5 days ago - Upstream Bio Quarterly report: Q3 2026 - Filings
- 7 weeks ago - These beaten-down stocks could bounce back in January, if history is any guide - Market Watch
- 2 months ago - Upstream Bio presents results from VALIANT trial at ERS Congress - TheFly
- 2 months ago - Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026 - GlobeNewsWire